Protara Therapeutics, Inc. (NASDAQ:TARA) Stock Has Consensus Price Target of $26.25

Protara Therapeutics, Inc. (NASDAQ:TARA) has received a consensus recommendation of “Moderate Buy” from the eight brokerages that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation and seven have given a buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is $26.25.

A number of research analysts recently issued reports on TARA shares. Wall Street Zen upgraded shares of Protara Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, September 5th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Protara Therapeutics in a report on Thursday, October 15th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Protara Therapeutics in a report on Thursday, October 15th.

Protara Therapeutics Stock Up 9.9%

Shares of Protara Therapeutics stock opened at $2.56 on Friday. Protara Therapeutics has a 12-month low of $2.30 and a 12-month high of $7.82. The stock has a 50 day moving average price of $3.43 and a two-hundred day moving average price of $4.13.

Protara Therapeutics (NASDAQ:TARA) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.03). On average, analysts predict that Protara Therapeutics will post -1.40 EPS for the current fiscal year.

Institutional Investors Weigh In On Protara Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. WINTON GROUP Ltd lifted its position in shares of Protara Therapeutics by 16.7% during the 2nd quarter. WINTON GROUP Ltd now owns 32,800 shares of the company’s stock worth $125,000 after purchasing an additional 4,700 shares during the last quarter. Squarepoint Ops LLC bought a new stake in Protara Therapeutics during the 2nd quarter valued at approximately $69,000. Corient Private Wealth LP bought a new stake in Protara Therapeutics during the 2nd quarter valued at approximately $41,000. Velan Capital Investment Management LP boosted its stake in Protara Therapeutics by 0.4% during the 2nd quarter. Velan Capital Investment Management LP now owns 2,844,652 shares of the company’s stock valued at $10,867,000 after purchasing an additional 10,000 shares during the period. Finally, Public Employees Retirement System of Ohio bought a new stake in Protara Therapeutics during the 2nd quarter valued at approximately $113,000. 38.13% of the stock is owned by institutional investors and hedge funds.

About Protara Therapeutics

Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and rare diseases. The company’s work centers on investigational treatments intended to address conditions with significant unmet medical needs.

Protara’s lead product candidate is TARA-002, an investigational cell-based therapy derived from OK-432, a preparation based on a strain of Streptococcus pyogenes. The company is developing TARA-002 for non-muscle-invasive bladder cancer, a form of bladder cancer that has not invaded the bladder muscle, and for lymphatic malformations, rare abnormalities of the lymphatic system.

Protara conducts its research and clinical development activities primarily in the United States.